Related Experiment Video
Updated: Apr 29, 2026
07:39
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
Published on: August 16, 2021
3.3K
BET 1: levosimendan in septic shock
Emergency Medicine Journal : EMJ
|May 20, 2014
Summary
Levosimendan does not currently show evidence of improving outcomes in septic shock. Further research, including the LeoPARDS trial, is needed to determine its potential benefits in reducing mortality.
Area of Science:
- Critical care medicine
- Pharmacology
- Clinical research
Background:
- Septic shock is a life-threatening condition characterized by circulatory, cellular, and metabolic abnormalities.
- Levosimendan is a medication used to treat acutely decompensated heart failure and sometimes explored for its potential in septic shock.
Purpose of the Study:
- To evaluate the current evidence on the efficacy of levosimendan in improving outcomes for patients with septic shock.
- To synthesize findings from relevant studies to inform clinical practice and future research.
Main Methods:
- A shortcut review methodology was employed.
- Eight directly relevant studies were identified and analyzed.
- Data extracted included publication details, patient demographics, study design, outcomes, results, and limitations.
Main Results:
- The reviewed studies do not provide evidence that levosimendan reduces mortality in septic shock.
- Tabulated data summarizes key aspects of the included studies, highlighting their findings and weaknesses.
Conclusions:
- Current evidence does not support the use of levosimendan for reducing mortality in septic shock.
- The upcoming LeoPARDS trial is anticipated to provide crucial data that may alter this conclusion.
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
1.9K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.9K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.8K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.8K
01:22Heart Failure Drugs: Diuretics
1.6K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.6K
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
1.6K
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
1.6K
01:22Heart Failure Drugs: β-Blockers
2.6K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
2.6K
01:30Heart Failure V: Medical Management
624
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
624